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Abstract
Alphaherpesviruses are widespread in the human population, and include herpes simplex virus 1 (HSV-1) and 2, and
varicella zoster virus (VZV). These viral pathogens cause epithelial lesions, and then infect the nervous system to cause
lifelong latency, reactivation, and spread. A related veterinary herpesvirus, pseudorabies (PRV), causes similar disease in
livestock that result in significant economic losses. Vaccines developed for VZV and PRV serve as useful models for the
development of an HSV-1 vaccine. We present full genome sequence comparisons of the PRV vaccine strain Bartha, and two
virulent PRV isolates, Kaplan and Becker. These genome sequences were determined by high-throughput sequencing and
assembly, and present new insights into the attenuation of a mammalian alphaherpesvirus vaccine strain. We find many
previously unknown coding differences between PRV Bartha and the virulent strains, including changes to the fusion
proteins gH and gB, and over forty other viral proteins. Inter-strain variation in PRV protein sequences is much closer to
levels previously observed for HSV-1 than for the highly stable VZV proteome. Almost 20% of the PRV genome contains
tandem short sequence repeats (SSRs), a class of nucleic acids motifs whose length-variation has been associated with
changes in DNA binding site efficiency, transcriptional regulation, and protein interactions. We find SSRs throughout the
herpesvirus family, and provide the first global characterization of SSRs in viruses, both within and between strains. We find
SSR length variation between different isolates of PRV and HSV-1, which may provide a new mechanism for phenotypic
variation between strains. Finally, we detected a small number of polymorphic bases within each plaque-purified PRV strain,
and we characterize the effect of passage and plaque-purification on these polymorphisms. These data add to growing
evidence that even plaque-purified stocks of stable DNA viruses exhibit limited sequence heterogeneity, which likely seeds
future strain evolution.
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Introduction
Alphaherpesviruses are widespread in the human population,
with herpes simplex virus 1 (HSV1) and 2 causing oral and genital
lesions, respectively, while varicella zoster virus (VZV) causes
chicken pox and shingles [1–3]. In the agricultural industry, a
related veterinary alphaherpesvirus, pseudorabies virus (PRV),
causes similar disease in swine and significant economic cost due to
weight loss in infected adults and reproductive losses during
pregnancy and suckling [4,5]. As occurs with HSV and VZV,
PRV infection has higher morbidity and mortality rates for
neonates, with decreasing severity of disease as the age at onset of
infection increases [2,4,6]. PRV and VZV primarily infect via the
respiratory mucosa, while HSV-1 primarily infects at the oral
mucosa. VZV infection includes a viremic phase that yields
widespread vesicular lesions, while PRV and HSV are usually
non-viremic and spread predominantly by mucosal infection and
neuronal innervation. These alphaherpesviruses are widespread in
the population because of their tendency to infect neurons: they
establish lifelong latency in the host peripheral nervous system.
These latent neuronal infections may occasionally reactivate and
spread back the mucosal surfaces where the infection initiated.
After further replication, the viruses can spread to new hosts.
Among alphaherpesviruses, vaccines are available for VZV and
PRV, but not HSV [7,8]. Despite considerable effort and recent
progress, no broadly effective vaccine candidates have yet emerged
for HSV infection [9–11]. The co-morbidities of HSV-1 and
HSV-2 with human immunodeficiency virus (HIV), which include
increased acquisition of HIV due to the inflammation and lesions
caused by HSV infection, have added impetus to the search for a
vaccine [10–13]. PRV serves as a useful model for HSV
pathogenesis and vaccine development, because of their similar
infectious cycle and ability to infect a variety of animal models
[4,5,8,14–17]. In contrast, VZV has a more restricted tropism for
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The agricultural importance of PRV and relative ease of vaccine
testing has led to the development of several PRV vaccine strains,
whose genetic characteristics have been determined by mapping
isolated genomic fragments and sequencing of select regions
[8,21–23]. Of note, the vaccine strain Bartha has a well-
characterized deletion of several viral proteins that attenuates its
virulence and also limits its spread in neurons, which led to its
subsequent development as a tool for trans-neuronal tracing
[21,24–27]. Like several other early vaccine strains, PRV Bartha
was attenuated by extensive passage in the laboratory, thus making
the full discovery of its genome-wide mutations a priority
[22,23,28,29]. Because the only available PRV genome sequence
to date is a mosaic of six strains [30], it has been difficult to discern
whether mutations detected in PRV Bartha and other vaccine
strains are unique or represent ordinary sequence diversity, i.e. are
found in other wild-type genomes [31–35]. We therefore applied
our recent success in using Illumina high-throughput sequencing
(HTS) to obtain HSV-1 strain genomes to determining the
sequence diversity in the PRV vaccine strain Bartha.
In addition to sequence polymorphisms, insertions, and
deletions, another major class of variation between nucleic acid
sequences lies in copy number variation, either of coding
sequences or of repeated structural elements. Herpesvirus genomes
have long been known to contain several sites with tandem short
sequence repeats (SSRs) or reiterations [36–40]. Variation in these
elements has been described both within and between herpesvirus
strains, but their functions were largely unexplored [22,35,41–43].
SSRs can be transcription factor binding sites, chromatin
insulators, protein folding motifs, or other regulatory elements
[44,45]. Recent studies have shown that SSR expansion and
contraction, most likely through recombination or polymerase
slippage, can generate phenotypic variation [46–49]. A range of
human diseases result from SSR expansion or contraction,
including the transcriptional silencing of the gene FMR1 via an
upstream SSR, which causes Fragile X syndrome, and the poly-
glutamine tract expansion in huntingtin protein, which causes
Huntington’s disease [50–53]. Limited explorations of repetitive
elements in viral genomes suggest that SSRs in viral genomes
likewise play functional roles [54–57]. To explore SSR prevalence
and function in herpesviruses, we initiated a global SSR
assessment and comparison across viral species, as was recently
done for a variety of fungal and bacterial pathogens [49,58]. These
data highlight the contribution of SSRs to overall sequence
diversity in viruses, and through the presence of these elements in
both coding and non-coding regions, suggest that viral SSRs may
likewise have the potential to affect gene expression and protein
functions.
We sequenced three widely-studied PRV isolates by HTS: the
attenuated vaccine strain Bartha and the virulent strains Kaplan
and Becker. This analysis reveals genome-wide sequence diversity
between strains, both in the PRV proteome and also in many
SSRs. Our comparison of protein coding sequences revealed that
46 of 67 PRV proteins have changes in the vaccine strain Bartha
which are not found in the virulent Kaplan or Becker strains. We
mapped homologous SSRs in all three strains and provide a
comprehensive overview of inter-strain variation in SSR length.
We compared the proportion of SSRs in PRV to those found in
HSV-1, VZV, the human betaherpesvirus cytomegalovirus
(HCMV) and gammaherpesviruses Epstein-Barr virus (EBV) and
Kaposi’s sarcoma-associated herpesvirus (KSHV), and Mimivirus.
We find that SSRs are likely to be a common property of these
large DNA viruses. Finally, we examined the limited number of
polymorphic bases detected in these plaque-purified virus stocks,
and tested the rate of polymorphism occurrence in purified and
non-purified virus populations. These data on sequence variation
in PRV strains expand our understanding of viral genome
diversity and how attenuated strains lead to successful anti-viral
vaccines.
Results/Discussion
Sequencing and assembly of multiple PRV strain
genomes
We used Illumina deep sequencing and bioinformatic analyses
to assemble millions of sequence reads into three completed
genomes of PRV Kaplan, Becker, and Bartha. To produce
genetically homogeneous stocks for sequencing, we purified a
single plaque from each virus stock, plated it out, selected a
progeny plaque, and repeated the process. These plaque-purified
stocks were then used to produce viral nucleocapsid DNA for
Illumina genomic DNA libraries. Over 15 million Illumina
sequence reads were combined for each strain (details of HTS
sequence reads for each strain are listed in Table S1 in Text S1).
High quality viral sequence data were used for a 3-phase de novo
assembly process (see Methods for details): 1) the automated
generation of large blocks of continuous sequence, or contigs, from
Illumina sequence data (usually 0.1–30 kilobase pairs (kb) in
length), 2) the automated generation of super-contigs (1–60 kb)
using a long-read assembler, and 3) the manual curation of gaps,
joins, and annotations. Assembly quality was checked by BLAST-
based alignment of each new genome versus the prior mosaic
reference. PCR-validation confirmed regions of the assembly with
greatest divergence from the mosaic strain, and guided genome
correction in selected regions of the assembly (Figure S1 and Table
S2 in Text S1). The resulting genomes resembled the original
mosaic genome in overall size and gene content (Figure 1A). The
Author Summary
Alphaherpesviruses such as herpes simplex virus (HSV) are
ubiquitous in the human population. HSV causes oral and
genital lesions, and has co-morbidities in acquisition and
spread of human immunodeficiency virus (HIV). The lack of
a vaccine for HSV hinders medical progress for both of
these infections. A related veterinary alphaherpesvirus,
pseudorabies virus (PRV), has long served as a model for
HSV vaccine development, because of their similar
pathogenesis, neuronal spread, and infectious cycle. We
present here the first full genome characterization of a live
PRV vaccine strain, Bartha, and reveal a spectrum of unique
mutations that are absent from two divergent wild-type
PRV strains. These mutations can now be examined
individually for their contribution to vaccine strain
attenuation and for potential use in HSV vaccine
development. These inter-strain comparisons also revealed
an abundance of short repetitive elements in the PRV
genome, a pattern which is repeated in other herpesvirus
genomes and even the unrelated Mimivirus. We provide
the first global characterization of repeats in viruses,
comparing both their presence and their variation among
different viral strains and species. Repetitive elements such
as these have been shown to serve as hotspots of variation
between individuals or strains of other organisms,
generating adaptations or even disease states through
changes in length of DNA-binding sites, protein folding
motifs, and other structural elements. These data suggest
for the first time that similar mechanisms could be widely
distributed in viral biology as well.
Inter-Strain Diversity of Alphaherpesviruses
PLoS Pathogens | www.plospathogens.org 2 October 2011 | Volume 7 | Issue 10 | e1002282Figure 1. Genome organization of PRV Kaplan and comparison of sequence conservation with strains Becker and Bartha. A) Open
reading frames (ORFs) are plotted spatially along the genome, along with their untranslated regions (UTRs). The genome proceeds from the Unique
Long (UL) region into the Unique Short (US) region, with US being flanked by long inverted repeats (IR, TR). The large-latency transcript (LLT) is not
translated. A horizontal bar connects the spliced portions of the UL15 ORF; splicing in the 59 UTR of US1 is not shown for space reasons. B) Graph
depicts DNA sequence conservation between PRV Kaplan and PRV Becker or PRV Bartha. Conservation is calculated from a multiple sequence
alignment, and the conservation score between any two genomes is plotted from a sliding 100 bp window. C) Short sequence repeats (SSRs) are
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unique short (US) region, with large inverted and terminal repeats
(IR, TR) flanking the US region. Overall, DNA sequences are
largely conserved between PRV Kaplan, Becker, and Bartha, with
the greatest foci of divergence occurring in IR/TR and noncoding
regions (Figure 1B). Phylogenetic comparison of the three full-
length genomes revealed a closer relationship between PRV strains
Kaplan and Bartha than PRV Becker (Figure 1D).
To ascertain the quality and depth of coverage of these new
genomes, sequence reads were aligned back to the assembled
genomes. Median coverage was very high: 3,704 sequence reads
per base for PRV Kaplan, 4,145 reads/base for Becker, and 4,137
reads/base for Bartha (see also Table S1 in Text S1). This
coverage was reduced in genome regions with extremely high or
low G/C content, as has been observed for both eukaryotic and
bacterial genomes (Figure S2A,B in Text S1) [59,60]. In addition
to analyzing coverage depth, the resulting genomes were used to
predict restriction digest patterns, which were compared to actual
restriction fragment length polymorphism (RFLP) patterns
(Figure 2). Digest patterns match the predicted fragment sizes,
with the exception of two classically variable fragments (BamHI 10
and 12; Figure 2) that have been observed to differ even between
repeated passages of the same strain [22,41,42].
Genetic differences and pathogenicity in the vaccine
strain PRV Bartha
PRV Bartha displays the most divergent phenotype of the PRV
strains sequenced here, with severe attenuation of virulence in vivo
conferring its suitability for use as a vaccine strain. We compared
all protein coding regions of PRV Bartha and the two wild-type
strains PRV Kaplan and Becker, to search for novel sequence
differences corresponding to potential effects on pathogenicity and
attenuation of the vaccine strain (Tables 1–3). Prior studies
mapped a deletion in the Bartha US region that removes all of gE
(US8) and US9 and creates an fusion of gI (US7) and US2, as well
as subtle variations in gC (UL44), gM (UL10), and UL21
[21,28,31,61–65]. Our de novo assembled Bartha genome confirms
the boundary of the US region deletion (position 120,927 on the
plotted as they occur along the PRV Kaplan genome. SSRs include minisatellites (repeat unit $10 bp), microsatellites (repeat unit ,10 bp), and
homopolymers (minimum length 6). D) A phylogenetic tree based on a whole-genome multiple sequence alignment demonstrates the closer
relationship of PRV strains Kaplan and Bartha. Bootstrap values are shown at branch points (see Methods for details). The same result was obtained
using nucleotide sequences of gC (data not shown), as was done for several recent PRV phylogenetic comparisons [33,34,177].
doi:10.1371/journal.ppat.1002282.g001
Figure 2. BamHI RFLP confirmation of PRV genome assemblies. A) Location of major BamHI fragments along the PRV Kaplan genome.
Fragments are identified by historical fragment numbering [41]. Genome position in kilobase pairs (kb) is listed below the fragments, with the large
inverted repeats IR and TR shown as green boxes. B) RFLP analysis of BamHI fragments of PRV strains Kaplan (Ka), Becker (Be), Bartha (Ba), an
unpurified Kaplan stock (Ka*np), and a Becker stock passaged 10 times in vitro (Be*p10). Positions of a standard marker are noted on the left. Major
BamHI fragments, and their predicted size in each strain, are indicated to the right at their approximate height in the gel image. The Bartha deletion
causes a major size shift in BamHI fragment 7 (boxed; now 3.1 kb); the new band co-migrates with BamHI fragment 11 (also 3.1 kb). All bands except
the variable fragments 10 and 12 (red asterisks) match their predicted sizes. Arrows from Kaplan through Becker and Bartha columns indicate bands
that are predicted to be of equivalent size in all three strains.
doi:10.1371/journal.ppat.1002282.g002
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PLoS Pathogens | www.plospathogens.org 4 October 2011 | Volume 7 | Issue 10 | e1002282Table 1. Protein-coding variations unique to the vaccine strain PRV Bartha, in comparison to the virulent strains PRV Becker and
Kaplan.
Gene
a Amino acid residues found in PRV Bartha, which differ from PRV Becker & Kaplan
b
ICP27 (UL54) G9D, T258A
UL52 A824V
dUTPase (UL50) S20G
gN (UL49.5) L7P
VP22 (UL49) T126A, 129(+A)
VP16 (UL48) Q171R, T386A
VP13/14 (UL47) V7A, E63D, E84G, 96–99(EEEE.D), Y144H, P432A
VP11/12 (UL46) W108R, 301–304(AAVV.D), 508–509(GE.D), A532T
gB (UL27) Y267H, R440Q, 506–507(SP.AA), P509Q
ICP18.5 (UL28) A517V
UL32 W266R, A289V
UL33 7(+G)
UL34 D188G, Y221C
VP26 (UL35) H65R
VP1/2 (UL36)
c T811A, L2152P, 2180(+EPTPAAKLAPPAPPPAKPA*)2, L2182T, H2219P, P2314L, K2449R, V2465A,
T2666A, 2686(+PGDDVVPA), V2853F, E2876G
RR1 (UL39) S95N, T294A
RR2 (UL40) G266D
vhs (UL41) M353V
UL42 E331A
gC (UL44) L14P, E43A, P156S
scaffold (UL26.5) 120(+Q)
VP24 (UL26) 365(+Q)
gH (UL22) V59D, P438S, 481–482(EE.G)
UL21 H37R, E355D, V375A
UL17 G239D, S341G, P521L
UL15 K404R
UL14 Q18R
V18.8 (UL13) A13V
AN (UL12) 178(+GD), V474A
UL11 Y49C
gM (UL10) 59–60(TS.AP)
OBP (UL9) D4P, 6–7(GG.RV)
UL8 A52V, V509I
UL6 4(+AA)
UL5 A2D
UL3.5 H94Q, R193H
UL3 T97D
UNG (UL2) A286S
ICP4 (IE180) Q92D, R195D, S234P, N296S, L319P, 371(P.LA), S752A, 854(+ESGSST), S954D, V1218A, H1390R
ICP22 (US1) V31L, 239(+DEDEEEEE), 254(+DEDGLCEDE)
gG (US4) 306–307(RG.HR)
gD (US6) V69A, N82S
gI (US7), gE (US8), US9, US2 Bartha deletion region
aProteins are listed in order of occurrence along the genome (see Figure 3 for full list and functions). Table 2 lists proteins with AA differences from PRV Kaplan that are
shared by PRV Bartha and Becker strains.
bBold indicates AA differences discussed in the text. Single AA residues changes are written in standard format, including the Kaplan reference strain AA, its position,
and the AA residue found in Bartha’s protein sequence, e.g. S100P. Insertions in PRV Bartha are indicated by the AA position in Kaplan followed by ‘‘+’’ and the new
AAs, e.g. 100(+RR). Deletions are indicated by the symbol D. Sequential changes are combined and shown with the Kaplan strain AA positions first, followed by the
relevant Kaplan AA residues, then ‘‘.’’, and finally the new alternative AA residues, e.g. 100–102(RAR.EDA).
cSubscript on parentheses in UL36 indicates multiple copies of a repeating unit.
*Final alanine (A) in this repeat unit changes to valine (V) in the second copy of the repeat unit.
doi:10.1371/journal.ppat.1002282.t001
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ing [66]; this region spans 3,482 bases on the reference PRV
Kaplan genome (positions 120,363–123,845; see also Figure 1B).
Adding to these previously reported findings, we identified a total
of 46 proteins with coding differences that are unique to PRV
Bartha and not found in either wild-type strain (Table 1 and
Figure 3). Several of these amino acid (AA) changes are
conservative, such as a minor Ala13Val change in Bartha’s
VP18.8 (UL13), or represent expansions or contractions associated
with AA repeats (e.g. VP1/2/UL36, ICP4/IE180, AN/UL12).
Many mutations affect loosely mapped functional protein
domains, for instance two differences in the 300 AA chemokine-
binding domain of Bartha’s gG [67]. Further studies will be
necessary to define any functional effects in these regions.
Several unique Bartha mutations are located within functional
domains of proteins not previously considered to affect Bartha’s
virulence and spread phenotypes, including gH (UL22), gB
(UL27), and gN (UL40.5). The core fusion process of most
alphaherpesviruses consists of receptor binding via gD (US6),
followed by fusion mediated by gB (UL27) and the gH-gL (UL1)
heterodimer. PRV gH has recently been crystallized, as have the
homologous gH proteins of HSV-2 and Epstein-Barr virus (EBV)
[68-70]. PRV Bartha has a Pro438Ser change in gH. In the recent
crystal structure of PRV gH, this proline was highlighted as a key
residue, because it mediates a bend at the end of an alpha helix in
the gH core (domain III), which is necessary to allow one of four
disulfide bonds in the protein [70]. This proline and the
neighboring disulfide-bonded cysteine are absolutely conserved
across all known herpesvirus sequences, including the evolution-
arily distant beta- and gamma -herpesviruses [70]. In Western blot
analysis of infected cell lysates (Figure 4), PRV Bartha produces
two bands of gH protein that are comparable to those of the PRV
Kaplan and Becker strains. There is no obvious difference in gH
produced by these PRV strains.
We also detected three changes to the key fusion protein gB
(UL27) coding sequence in PRV Bartha, which affect several
residues immediately adjacent to gB’s furin cleavage site
(Ser506Ala, Pro507Ala, and Pro509Gln). Furin cleavage of gB
has been shown to affect cell-cell spread of PRV and in vivo
virulence of VZV [71,72]. Transfer of just 11 AAs surrounding
this furin cleavage site, corresponding to residues 497–507 of the
PRV Kaplan gB sequence (PAAARRARRSP), are sufficient to
confer protease-cleavage when inserted into PRV gC [73]. As
noted previously [31], gB is still cleaved in PRV Bartha-infected
cells in vitro (Figure S3 in Text S1), but it is unknown whether these
changes in gB affect cleavage efficiency or other aspects of gB
function in specialized cell types such as neurons.
Finally, PRV Bartha has a Leu7Pro alteration in the signal
sequence of gN (UL49.5) that may affect glycoprotein processing
and/or packaging [62,74]. A previously detected Leu14Pro
Table 2. Protein-coding variations shared by the vaccine strain PRV Bartha and the virulent strain PRV Becker, in comparison to the
reference strain PRV Kaplan.
Gene
a Amino acid residues found in PRV Bartha and Becker, which differ from PRV Kaplan
b
VP22 (UL49) G63D, A109T
VP13/14 (UL47) T75M, D115E, E124D, D126D, 129–130(GD.EE), 133–134(GD.EE), D140G, 151–158(ASRAAAGP.V), S176P, 230–233(STAA.D), T658A
gB (UL27) T556A
UL34 M172L, G181D
VP1/2 (UL36)
c G184S, G475E, G1886–1887(GA.AP), A2110T, A2468T, 2782(+PAPPPSR)3, L2886P, L2983P, 2993–2996(GDED.D)
UL43 A299T
gC (UL44) E99K, A181V
UL25 S36G, V231A
TK (UL23) V284A
gH (UL22) I539L
VP5 (UL19) P502A
UL17 R31A
UL15 A158D, 203(+RGRGGG)
V18.8 (UL13) V233F
OBP (UL9) T233A
UL5 A638P, M661V
UL3.5 Q115D
UL3 R42C, L61R, W104R
UNG (UL2) P82A
ICP4 (IE180) 69(+EA), T305P, S353G, 383–385(SSS.D), R747Q, S859G
ICP22 (US1) 299–300(ED.D), D302E, G322E
gG (US4) G348A
aProteins are listed in order of occurrence along the genome (see Figure 3 for full list and functions).
bSingle AA residues changes are written in standard format, including the Kaplan reference strain AA, its position, and the AA residue found in the alternative protein
sequence, e.g. S100P. Insertions are indicated by the AA position in Kaplan followed by ‘‘+’’ and the new AAs, e.g. 100(+RR). Deletions are indicated by the symbol D.
Sequential changes are combined and shown with the Kaplan strain AA positions first, followed by the relevant Kaplan AA residues, then ‘‘.’’, and finally the new
alternative AA residues, e.g. 100–102(RAR.EDA).
cSubscript on parentheses in UL36 indicates multiple copies of a repeating unit.
doi:10.1371/journal.ppat.1002282.t002
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PLoS Pathogens | www.plospathogens.org 6 October 2011 | Volume 7 | Issue 10 | e1002282Table 3. Protein-coding variations unique to the virulent strain PRV Becker, in comparison to strains PRV Bartha and Kaplan.
Gene
a Amino acid residues found in PRV Becker, which differ from PRV Bartha & Kaplan
b
ICP27 (UL54) H126R
gK (UL53) D78G
UL52 H208R, A512V, S600P, D606G, 666–667(LV.PA), P678A
UL51 S138N
dUTPase (UL50) L110P
VP22 (UL49) T28A, 30–31(TT.AA), 34(+VPT), 47–49(YDD.D), R74H, 123–126(TTTT.A)
VP16 (UL48) G55S
VP13/14 (UL47) 89–91(GDE.ADGD), 144–145(YD.RG)
VP11/12 (UL46) A236P, D637A
gB (UL27) 72–74(VPG.D), S75G, P76T, L78A, T96S, N445S, S496A, S682N, F709L
ICP18.5 (UL28) M58T, R225H, 252(+ASTAAA), A688G
ICP8 (UL29) A1146V
UL34 G185D
VP1/2 (UL36)
c A249G, 266–272(AAAPAPA.D), P281S, P1083S, 2169(+APAAPAAPPPAKPAEPTPAAKL), L2182P, T2324A, 2326(+TAAT), T2334N, 2404–
2417(PPSAQTTLPRPAPP), L2475F, T2535A, 2669(+A), 2762-2763(AA.VV), A2767T, T2772S, A2785P, V2853L
RR1 (UL39) D358G, A376T
RR2 (UL40) G107N, E123G, E138A, A140E, V142I, D209S
UL43 L239F, V311A
gC (UL44) G30D, 68–69(RA.PV), T179A, 183–184(ED.V), G187E, D317A, R477Q
scaffold (UL26.5) 129(+HP), A203D, 244(+AP)
VP24 (UL26) 375(+HP), A449D, 490(+AP)
gH (UL22) L58P, S201A, E478G, 480(+EE)
UL21 347–349(DDP.L)
UL17 E178K
UL16 A120G, P121A
AN (UL12) R124H
UL11 A62V
gM (UL10) A292T
OBP (UL9) 255–257(AGA.D), S266G, A281T, 284–285(TA.AV), E653G
UL8 A3T, G125D, E138G, L331F, I647V
UL7 R148Q
UL6 E183D, A463G
UL5 P580D
UL4 S21P, V118A
UL3.5 A38T, P53H, Q95H, 113–114(QQ.D), G132D, H189N, A199T, A201T
UL3 P50R, D69G, T97A, 153–155(ARR.D), P159A
UNG (UL2) A27D, S55P
gL (UL1) T20P, H27R, P35A, A45H, G62D, T84N, I122V
ICP0 (EP0) Q33L, S34T, A172T
ICP4 (IE180) P182S, P229S, N294S, T298A, P327L, 371(+AA), 436(+AAS), A792G, S851G, A909S, 947(+SSS), E991A, G1195E,
T1355A, V1359L, L1369R, A1393S, S1396R, A1398P, 1400–1402(AGP.ED), 1406–1408(GDS.SAA), V1414F
ICP22 (US1) 1(+DR), 4(V.A), R84H, E237A, 244–260(GETDVYEEDDEAEDEED.D), 333(+ED)
PK (US3) 27(+GD), A45S, V48A, Q97K, S100A, 106–107(RM.SL), A116V, C146R, A150S, T242A
gG (US4) A244V, L249S, T484I
gD (US6) I122V, N207S, E209D, R212K, 266(+PR), V284A, G290D, H305R, T391A
gI (US7) Q207P, L210I, A249V, V255A, D257G, 260(+L), S281G, S337N
gE (US8) T124M, R162Q, Q180R, T299A, G446A, V499D
US9 P24A
US2 L130I, V146I, T182A
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to inefficient maturation of gC, and reduced incorporation of gC
into virions [62]. PRV gN is normally packaged into virions and
affects the rate of virion penetration into cells [74,75]. If this signal
sequence mutation affects gN maturation or virion inclusion in a
parallel way to that of the gC signal sequence mutation, it may
well contribute to the delayed penetration kinetics and cell-to-cell
spread phenotype of the attenuated PRV Bartha vaccine strain.
Amino acid variation between strains of PRV, HSV-1, and
VZV
The genomes of alphaherpesviruses have long been thought to
be quite stable with limited sequence variation among strains
[76,77]. This idea was well supported when the genome-wide
comparison of 18 VZV strains revealed inter-strain coding
variation of 1% or less [78,79]. The four HSV-1 genome
sequences available show modestly increased inter-strain protein-
coding variation [80-83]. Surprisingly, we find that protein coding
variation between PRV strains is higher than that observed for
either HSV-1 or VZV (average of 1.6% for PRV, vs. 1.3% for
HSV-1 or 0.2% for VZV; Figure 5 and Table S6) [78,81]. When
the coding sequences for each protein of these three new PRV
genomes are compared, the inter-strain variation in AA sequence
(number of AA residues varying between strains, normalized for
protein length) reaches as high as 13%. Starting on the low end of
variation, we found eight invariant proteins across these PRV
strains (Figure 3), including the viral DNA polymerase UL30, the
minor capsid proteins VP19c (UL38) and VP23 (UL18), the
nuclear egress components UL20, UL31, and UL37, and the
functionally uncharacterized proteins UL24 and UL56 (ORF-1).
In contrast, ICP22 (US1) displays 13% inter-strain variation; this
protein has transactivating and regulatory functions in related
alphaherpesviruses [84,85], but has only been studied at the level
of transcript expression in PRV [86,87]. In a similar comparison of
AA sequence differences between 3 strains of HSV-1, the inter-
strain variation peaked at 7% (for ICP34.5 (RL1) and US11; Table
S6) [81]. VZV strains show even less variation in protein coding
sequences, with a maximum of 1.2% AA variation (in ORF-1)
between strains, and just two additional proteins with variation
greater than 0.5% [78]. One of these two VZV proteins is ORF
62/71, which is homologous to PRV IE180 and HSV-1 ICP4; this
protein is among the most variable across all known strains of these
alphaherpesviruses. IE180 is the sole gene expressed with
immediate-early kinetics in PRV, and is a key transactivator of
viral gene expression [88–90]. In contrast, the nuclear egress
proteins UL20 and UL31 thus far shows no inter-strain variation
in all known genomes of PRV and HSV-1, while UL31 shows zero
coding variation in VZV as well.
A comparison of the inter-strain variation in homologous
proteins of PRV and HSV-1 (Figure 5 and Table S6) highlights
several proteins that appear to vary more substantially in one virus
than the other. Although ICP22 is the most variable protein in
PRV, it is completely invariant among HSV-1 strains 17, F, and
H129, as well among the previously described 18 strains of VZV
[78,79,81]. Likewise, the viral egress protein VP13/14 (UL47) is
among the most variant in PRV, but it is well-conserved in HSV-
1, while the opposite is true for HSV-1 proteins uracil-DNA
glycosylase UNG (UL2) and the ubiquitin E3 ligase ICP0 (EP0)
(Figure 5, orange vs. green highlighting). Several proteins, which
do not have homologs between HSV-1 and PRV, are also highly
variable; these include PRV’s viral egress protein UL3.5, which
has the third-highest variability of PRV proteins after ICP22 and
the tegument protein VP22 (UL49), and the two most variable
HSV-specific proteins, which are the neurovirulence-associated
protein ICP34.5 (RL1) and the PKR-antagonist US11.
Short sequence repeats (SSRs) are prevalent in the PRV
genome
SSRs are widespread in eukaryotic genomes, and mediate
functional effects by serving as DNA-binding domains in
promoters, protein folding motifs in coding sequences, and sites
of inter-molecular recombination [44–47]. Since AA repeats
generated several examples of inter-strain coding diversity above
(Tables 1–3), we investigated the prevalence of SSRs in the PRV
genome. SSRs are generally grouped into three main categories:
homopolymers, which include a short run of the same base;
microsatellites, where the repeating unit is less than 10 bases; and
minisatellites, which have a repeating unit of 10–500 bases
[44,45]. The initial description of the PRV genome mapped 26
minisatellite SSRs using a DNA identity scoring matrix [30].
Using software designed to identify all size classes of SSRs and
include both perfect and imperfect repeats (see Methods for
details), we detected a significantly larger number of repeats, a
total of 953 distributed across the PRV Kaplan genome (Table 4
and Table S7; minimum homopolymer length 6). SSRs in PRV
occur in both coding and non-coding regions, promoters and open
intergenic space, with similar proportions in all three PRV strains
(Table 5 and Figure 6A). SSRs of all size classes are distributed
throughout the genome, with a slightly higher accumulation of all
types in the IR-US-TR region (Figure 1C and Figure S4 in Text
S1). The majority of all SSRs in PRV (62%) contain triplet-based
repeats (e.g. the repeat unit is a 3-mer, 9-mer, 21-mer, etc.).
Likewise, 69% of homopolymers have a triplet-based length. Half
of all SSRs are in coding sequences (474/953), and these are
largely triplet-based (72%). Triplet-based repeats, as well as
insertions or deletions (indels) and partial repeat units of non-
triplet-SSRs, help preserve the coding content in the SSR-laden
PRV genome because variation in these repeats (addition or
removal of repeat units) does not change the reading frame of the
downstream sequence.
All coding sequences, except the small UL11 gene, contain
SSRs (Figure 1C). However it is interesting to note that nineteen
genes are free of homopolymers, a size class where expansion or
contraction of the SSR is likely to disrupt the reading frame (Table
S7). Likewise another 20 genes have regions of at least 1 kb that
are homopolymer-free. For instance, the large tegument protein
VP1/2 (UL36; 9.2 kb in length) has no homopolymers in its initial
5.5 kb (Figure 1A,C), which contains several domains affecting
capsid transport, replication, and neuroinvasion [91–95]. In
aProteins are listed in order of occurrence along the genome (see Figure 3 for full list and functions).
bSingle AA residues changes are written in standard format, including the Kaplan reference strain AA, its position, and the AA residue found in the PRV Becker protein
sequence, e.g. S100P. Insertions are indicated by the AA position in Kaplan followed by ‘‘+’’ and the new AAs, e.g. 100(+RR). Deletions are indicated by the symbol D.
Sequential changes are combined and shown with the Kaplan strain AA positions first, followed by the relevant Kaplan AA residues, then ‘‘.’’, and finally the new
alternative AA residues, e.g. 100–102(RAR.EDA).
doi:10.1371/journal.ppat.1002282.t003
Table 3. Cont.
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PLoS Pathogens | www.plospathogens.org 8 October 2011 | Volume 7 | Issue 10 | e1002282Figure 3. Protein coding variation in PRV Bartha and Becker, vs. the reference strain Kaplan. The percent of AAs differing in PRV Becker
and Bartha, vs. the new reference genome of PRV Kaplan, are plotted in order of occurrence along the PRV genome (top to bottom). Eight proteins
show no inter-strain variation in coding sequence. The total number of differences (Tables 1–3) have been normalized to protein length. Protein
names and functions are listed on the left, along with a symbol indicating if the protein product is a known virion component. AA differences from
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previously shown to be dispensable for viral replication [96]. Of
the 25 core genes found across multiple families of Herpesviridae that
are essential for growth in cell culture [76], 18 have no
homopolymers or regions .1 kb that are homopolymer-free. As
additional sequences become available for phylogenetic compar-
ison, it may be possible to determine whether this is a chance
occurrence or the result of purifying selection.
Since SSRs have not been comprehensively examined in other
DNA virus families, we extended these analyses to include the
genomes of a wide variety of human herpesviruses, including
HSV-1, VZV, HCMV, EBV, and KSHV (Table 4 and Figure 6B–
D). To ascertain if these results hold for non-nuclear, non-
mammalian viruses, we selected as an outgroup for comparison
the nucleocytoplasmic large DNA virus Mimivirus, which infects
pathogenic amoebae (Figure 6E) [97]. PRV has the highest overall
SSR burden, with short repeats encompassing 18% of the genome,
which is roughly double the proportion found in HSV-1, EBV,
and Mimivirus, and 5–6 times that of VZV, HCMV or KSHV. In
all of these viruses, more than half the SSRs fall into coding
regions (Figure 6), creating potential effects on protein structure if
these SSRs vary in length between strains. SSRs also occupy a
noticeable fraction of the intergenic and promoter regions in PRV
and other genomes (Figure 6). For those genomes with a biased
nucleotide content, the bias is exaggerated in SSRs (Table 4).
PRV’s overall genome is 74% G/C, but this level is 79% when all
SSR sequences are pooled together. This is similar in HSV-1 (68%
G/C overall; 84% in SSRs) and EBV (59% G/C overall; 77% in
SSRs), and mirrored in reverse in the A/T-rich genome of
Mimivirus (72% A/T overall; 80% in SSRs). PRV thus provides a
rich set of SSRs for analysis of a phenomenon that extends to
many other viruses.
Previous work in yeast, humans, and other organisms has
demonstrated that variation in SSR length, either between
individuals or during evolutionary adaptation, can result in
phenotypic effects [47–50]. Although the overall proportions of
SSRs are similar in the PRV Kaplan, Becker, and Bartha genomes
(Figure 6A), a comparison across PRV strains revealed that
homologous SSRs vary in length between strains (Table 5).
Previously, variation in a selection of microsatellites (#6 bases in
length) has been shown for HSV-1, HCMV, and HIV [98–100],
but the genome-wide complement of all SSR types has not been
analyzed. The comparison of homologous SSRs reveals that not
all SSRs can be recognized in all three strains (e.g. SSRKa151,
SSRKa2093, and SSRKa62103 in Table 5). However the majority of
those that do occur in all strains vary in the number of repeating
units (of 861 SSRs found in all three strains, 539 vary in number of
repeating units). If these SSRs contain transcription factor binding
sites or occur in protein coding regions, then these inter-strain
differences in SSR copy number may influence gene expression or
protein folding domains, and thus lead to phenotypic differences
between strains.
Inter-strain variation in SSRs containing CTCF DNA-
binding sites
One of the best characterized biological roles for SSRs in
herpesviruses are the CCCTC-binding factor (CTCF) binding sites
that flank latency-associated transcripts in the genomes of HSV-1
and the gammaherpesviruses EBV and KSHV [101–108]. In each
of these cases, CTCF binds to motifs within SSRs found near loci
that are transcriptionally active during latency; this interaction is
proposed to have chromatin insulating and/or silencing effects
that maintain a repressed state in flanking genes. CTCF-binding
sites occur in several additional conserved locations throughout
alphaherpesvirus genomes, as shown by Amelio et al. in a
comparison that included HSV-1, VZV, and PRV [104]. Because
many PRV SSRs showed inter-strain variation in copy number or
length, we investigated CTCF-binding sites in PRV Kaplan,
Becker, and Bartha. Of the 17 CTCF binding sites mapped by
Amelio et al, 12 were mapped as falling into SSRs in our inter-
strain comparison (Table 5; CTCF-binding sites in the repeat-unit
consensus are underlined and in bold). All of these vary in repeat-
the reference strain Kaplan are categorized as being unique to the vaccine strain PRV Bartha (orange), unique to the virulent strain PRV Becker (blue),
or shared (observed in both Bartha and Becker; gray). The four proteins affected by the deletion in Bartha’s US region are bracketed at the bottom.
doi:10.1371/journal.ppat.1002282.g003
Figure 4. Inter-strain variation in protein levels of gH. A)
Western blot analysis of infected cell lysates demonstrates that PRV
Bartha produces gH (UL22) comparable to that in virulent strains. PRV
Becker displays slightly higher and/or differentially glycosylated levels
of gH than the other two strains. Levels of the capsid protein VP5 (UL19)
are shown for comparison and as a loading control. B) Ratio of gH vs.
VP5 in each sample, using the ImageJ Gel Analyzer module. Equivalent
amounts of protein were loaded in each lane. The blot was cut, with
VP5 measured on the upper half and gH on the lower half to
demonstrate equivalent levels of infection in each lysate. The same
lysates were used for the analyses in Figure S3 (in Text S1); these are
representative of three separate experiments. The conditions required
to visualize the two bands of gH precluded measurement of cellular
actin on the same blot. Positions of a standard marker are noted on the
left.
doi:10.1371/journal.ppat.1002282.g004
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SSRKa115550). Although several have diverged enough to be listed
as separate SSRs, their overall location and CTCF-binding ability
are preserved (e.g. Table 5: SSRKa115377 and SSRBe115911; see
Table S7 for orthologous SSRBa115943). The greatest inter-strain
variation in SSR length occurs at SSRKa15795, between UL46 and
gB (UL27), where PRV Becker has three times as many repeating-
units as either PRV Kaplan or Bartha. This SSR contains both
CTCF-binding sites and a non-canonical Egr1/2 binding site,
both of which have repressive effects on expression of nearby genes
in HSV-1 [57,104,109–111]. Initial studies show that gB levels in
PRV Becker-infected lysates do not appear significantly lower than
those in PRV Kaplan or Bartha (Figure S3 in Text S1). Further
work will be required to determine if the flanking SSR length
affects gB expression and function.
In the only previous publication comparing full-length genomes
of HSV-1 (strains 17, H129, and F), the length of fourteen major
SSRs throughout the genome were not determined and were
instead set to match the reference genome length [81]. These
fourteen SSRs, classically termed reiterations in the HSV literature
[37,38,82,83], correspond to the fourteen CTCCC-domain-
containing SSRs defined by Amelio et al. [104]. To discern if
inter-strain variation such as that observed in the PRV genomes is
found in HSV-1 as well, we PCR amplified and sequenced two of
these SSRs from the HSV-1 strains F and H129. Both SSRs
displayed inter-strain variation in copy number, with the reference
Figure 5. Inter-strain diversity in protein coding sequences, in PRV as compared to HSV-1. The total number of amino acid differences
between three strains of PRV (strains Kaplan, Becker, Bartha) is normalized for protein length and plotted with data for the homologous proteins of
HSV-1 (strains 17, F, H129) [81]. Blue color highlights variable proteins where inter-strain variation reaches similar levels in PRV and HSV-1, while
orange highlights proteins that are much more variable in PRV than HSV-1, and green highlights the converse. Boxed proteins UL31 and UL20 show
no variations in these six strains of alphaherpesvirus; UL31 also shows no coding variation across 18 strains of VZV [78,79]. Proteins without
homologues in both viruses are excluded, as are proteins in the Bartha deletion region. Table S6 lists all protein names, lengths, and percent variation
in PRV, HSV-1, and VZV strains.
doi:10.1371/journal.ppat.1002282.g005
Table 4. Comparison of ORF and SSR quantities in PRV, HSV-1, VZV, and Mimivirus.
Virus (official
acronym)
a Strain
b
Length
(bp)
% G/C overall
(in SSRs)
#
proteins
c
# mini-satellite
SSRs ($10 bp)
# micro-satellite
SSRs (,10 bp)
# homo-
polymers Ref.
PRV (SuHV-1) Kaplan 140,377 74% (79%) 69 382 230 341
d
HSV-1 (HHV-1) 17 152,261 68% (84%) 77 142 103 661
e
VZV (HHV-3) Dumas 124,884 46% (47%) 73 15 17 282
f
HCMV (HHV-5) Merlin 235,646 57% (57%) 165 104 49 343
g
EBV (HHV-4) Raji 171,823 59% (77%) 94 71 23 423
h
KSHV (HHV-8) GK18 137,969 54% (62%) 86 32 13 225
i
Mimivirus (APMV) Mimivirus 1,181,549 28% (20%) 979 1,220 230 5,265
j
aSuid herpesvirus (SuHV), Human herpesvirus (HHV), and Acanthamoeba polyphaga mimivirus (APMV).
bNCBI nucleotide records: PRV Kaplan, JF797218; HSV-1 17, NC_001806; VZV Dumas, NC_001348; HCMV Merlin, NC_006273; EBV Raji, NC_007605; KSHV GK18,
NC_009333; Mimivirus, NC_014649.
cGenes with duplicate copies in IR/TR are counted at both sites of occurrence. Reference sequences and protein data are from the NCBI Viral Genomes Project [185].
dThis work,
e HSV-1 [82,83],
f VZV [186],
g HCMV [187],
h EBV [188–192],
i KSHV [193],
j Mimivirus [125].
doi:10.1371/journal.ppat.1002282.t004
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units at both sites than either the clinical isolate H129 or the
laboratory strain F (IRS reiteration 3 [CTRS3 in Amelio et al.]: 6.5
copies in strain 17, 4.7 copies in H129, 1.7 copies in F; US
reiteration 1 [CTUS1 in Amelio et al.]: 10 copies in strain 17, 2
copies in H129, 2 copies in F). These data suggest that inter-strain
variation in SSR length may affect CTCF-binding efficiency in
HSV-1 and could contribute to inter-strain differences in related
phenotypes.
Estimation of selected SSRs by Coverage Adjusted
Perfect Repeat Expansion (CAPRE)
Annotation of SSRs in the draft PRV genome assemblies had
revealed several discrete areas in each genome where peaks of very
high coverage coincided exactly with perfect SSRs: for example a
peak of over 100,000-fold coverage around an SSR at position
15,600 in the PRV Becker genome (Figure S1 in Text S1 and
Table 5). This very high coverage (.2 standard deviations above
the median) occurred at three SSR sites in PRV Kaplan, three
SSRs in PRV Becker, and four SSRs in PRV Bartha. (Figure S1
and Table S3 in Text S1, also noted in Table 5). De novo assembly
methods cannot distinguish whether repeated sequence reads
originate from perfect, extended copies of an SSR unit, or from
additional coverage depth of a single unit, and the software
therefore creates a final assembly with the minimal number of
repeating units supported by the data [112]. In fact, the high
coverage peak in PRV Becker coincides with the largest SSR array
of perfect repeats in the original mosaic PRV genome, which had
39 copies of a 15-mer at this site [30], suggesting that this peak
might result from de novo-assembly compression of the homologous
SSR in PRV Becker. The short unit size of this SSR (15-mer)
meant that its copy number could only be estimated by RFLP and
Table 5. Comparison of selected short sequence repeats (SSRs) in PRV strains Kaplan, Becker, and Bartha.
IDstrain, genome
position
a Location
b
Kaplan
# units
Becker
# units
Bartha
# units Repeat unit consensus (unit length)
c
Intergenic:
SSRKa151 left terminus 3N F
d NF TACCTGGCACCCTGCCAA-
CCCCAATCCCCCTCC (33mer)
SSRKa2093 between ORF-1 & UL54 8.3
e NF 6 GGGGAGATGGGGAGAGGAGAT (21 mer)
SSRKa15795 between UL46 & UL27 13.7
e 59
e 18.4
e ACGGAGGGGAGAGGG (15 mer)
SSRKa31884 between UL35 & UL36 5.6 2.7 4.8 CCCCAAGTCCCCCAATCC (18 mer)
SSRKa62103 between UL22 & OriL 6.3 NF NF CGCCCTCTCTCCCAC (15 mer)
SSRKa62261 between UL22 & OriL 6.5 10.5 11.5
e AAGGGGTCTCT (11 mer)
SSRKa79207 between UL11 & UL10 6.4 7.4 8.1
e TGGGGGAGAGGA (12 mer)
SSRKa94997 between UL1 & EP0 17 18 15 GGAGCA (6 mer)
SSRBe100922 between left edge IR & IE180 2.1 3 3 CCCCCCCCCCCATTTGCATATGACCG-
CTTCCCCCGGACGTGACGCTCGGG (50 mer)
SSRBe101633 between left edge IR & IE180 3.3 3.1 NF GACCACCGGGACCACCAACA-
CCGTCTACCTCCCACCAG (38 mer)
SSRKa106596 promoter
f: IE180 3.2 NF 3.2 CGGCCAATGGGATTTCTCTCGCCAA-
CTTCCTCTCGCGTCTACTTTGCATGTCCG-
GCCCCCGCGGCGGCCATCTTGGCCCCTCGA
(84 mer)
SSRKa107138 between IE180 & OriS (in IR) 12.5
e 4.1 8.8 TGTGGTGGTCTCTGTGTTG (19 mer)
SSRKa115377 between US1 & edge of IR 3.1 NF NF GGGGAGTGGGATGGGGGTGGAGA-
CGGTGGAGGGAGA (36 mer)
SSRBe115911 between US1 & edge of IR NF 20.6
e NF GGTGGAGGGAGAGGGGGAC (19 mer)
SSRKa115550 promoter: US3 9 3 10 GGGGGAGTCC (10 mer)
In coding sequences:
SSRBe33478 UL36 1.4 5.2 5.4 GGGGCCGGCCGCGAAGGTGGT (21 mer)
SSRBa32980 UL36 1.1 NF 3.1 GGCCGGCCGCGAAGGTGGTGGG-
GCCGGCGGTGGTGC (36 mer)
SSRKa57529 UL25 3.2 3.2 3.2 CCTCGGGCGCCTCCTCGGCGGCGCGCG
(27 mer)
SSRKa114728 US1 72.8 63.8 80.2 CGAGGA (6 mer)
aRepeats selected have a TRF alignment score $100 and/or VarScore $1, with a repeat unit length $6a n d$3 repeat units. The PRV Kaplan genome was primarily used
for repeat screening, with additional searches run on the other genomes to detect SSRs with high scores in Becker or Bartha but not Kaplan. SSR identifier (IDs) denote
the strain name where the SSR was first detected (Ka, Kaplan; Be, Becker; or Ba, Bartha) and the start position on that genome. For clarity, only the IR copy of SSRs
falling into the large IR/TR repeats is shown (see Table S7 for a full listing of all SSRs).
bBoldface indicates SSRs previously noted in the initial description of the mosaic PRV genome [30].
cBoldface indicates CTCF binding sites within these SSRs, as defined by Amelio et al. [104].
dNF, not found. Indicates that a homologous repeat was not found in this strain or had diverged beyond detection.
eCAPRE was used to estimate repeat unit length of these perfect SSRs. See Figure S1 (in Text S1) and Methods for details.
fPromoter refers to sequences within 500 bp upstream of a start codon.
doi:10.1371/journal.ppat.1002282.t005
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could lead to laddering and polymerase slippage errors in PCR
analysis. We therefore devised an approach to computationally
estimate the length of these perfect tandem repeats that
demonstrate potential compaction during assembly, in order to
facilitate future HTS-genome assemblies and preserve coverage-
based information on inter-strain variation in SSR length.
Coverage-Adjusted Perfect Repeat Expansion (CAPRE) is based
on methods used for copy number variant estimation in HTS data
[113,114], which is used in larger genomes to detect duplications of
Figure 6. Prevalence of SSRs in PRV strains and in related DNA viruses. The proportion of bases in each genome involved in SSRs was
calculated for (A) all three PRV strains, as well as for (B) the related human alphaherpesviruses HSV-1 and VZV, (C) the betaherpesvirus HCMV, (D) the
gammaherpesviruses EBV and KSHV, and (E) a nucleocytoplasmic large DNA virus, Mimivirus. Pie charts depict what proportion of each genome falls
into coding regions, promoter regions (defined as 500 bp upstream of a coding sequence), or open intergenic regions. Exact numbers and types of
SSRs per genome are found in Table 4. A complete list of all PRV SSRs is found in Table S7.
doi:10.1371/journal.ppat.1002282.g006
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estimations, CAPRE takes into account the observed coverage
depth and estimates the length of intergenic SSRs based on the
expected sequence depth for its G/C nucleotide content (Figure
S2A in Text S1). In order to estimate SSR length conservatively,
CAPRE predicts SSR length based on the median coverage
expected for a given G/C content, and can also be used to predict
potential upper- and lower-range estimates based on the upper and
lower quartile ranges of this coverage (Figure S2A in Text S1).
Becauseitisimprecise,weappliedthismethodsparingly,andusedit
onlyatintergenicsiteswherecoverage depth exceededtwo standard
deviations from the median and coincided with a perfect SSR. We
used CAPRE to expand the lengths of three SSRs in PRV Becker,
three inKaplan,andfourinBartha(Figure S1and TableS3inText
S1). This did not affect the overall count of SSRs in Table 4, but did
affect the length of several SSRs included in Table 5 (e.g.
SSRKa15795; these are marked). We incorporated these CAPRE-
expanded SSRs into the overall assembly of each genome before
final annotation and comparisons. The CAPRE method provided a
means to estimate the length of these repeats and yielded a more
even distribution of sequence read coverage at these sites in the final
genome (Figure S1 in Text S1).
To test whether the CAPRE script provides a reasonable estimation
of SSR length, we compared the CAPRE-expanded SSRs to
alternative sources of data on actual SSR length. First, we compared
the three CAPRE-expanded SSRs of PRV Kaplan (Table S3 in Text
S1) to their counterparts in the original PRV mosaic genomes. Each of
these SSRs falls into areas of the mosaic genome that were originally
derived from the Kaplan strain, facilitating comparison of our
estimated lengths to SSR lengths that were determined in strain
Kaplan by traditional Sanger sequencing. For SSRKa107138,t h e
CAPRE-estimated length nearly matches that of the Sanger-
sequenced Kaplan isolate (12.5 copies here vs. 10.5 copies in the
mosaic), while for the other two it provides a conservative under-
estimate (SSRKa2093 is 8.3 copies here but was 17.3 in the mosaic;
SSRKa17595 is 13.7 copies here, but was 39 copies in the mosaic).
Next, we used RFLP and Southern blot analysis to estimate the
length of the most divergent SSR between strains (Table 5,
SSRKa15795); this SSR is also the only one expanded by CAPRE
for all three strains (Table S3 in Text S1; SSRKa15795, SSRBe15739,
SSRBa15751). We hybridized a probe to this SSR against SalI-
digested DNA from PRV Kaplan, Becker, and Bartha (Figure 7).
The size of the SalI fragment reflects a much larger size in PRV
Becker than in Kaplan and Bartha, and further reveals that this
SSR varies in length even within the purified PRV-Becker stock. A
prior Southern blot analysis by Simon et al. showed that this same
SSR varied in length between strains and within plaque isolates of
a given PRV strain [115]. As occurs here with strain Becker, those
authors found that the strain Phylaxia had a wide and blurry band
of probe hybridization, while other PRV strains (Kaplan and
Dessau) had tight bands [115], suggesting strain-specific differ-
ences in SSR length stability. To investigate the stability of this
SSR, we serially passaged the plaque-purified PRV Becker stock
ten times in culture (potentially 20–30 cycles of replication at low
multiplicity of infection (MOI); see Methods for details). RFLP
analysis of this stock, termed Becker p10, differed from the
parental PRV Becker only in the classically variable BamHI
fragments 10 and 12 (Figure 2B and 7A), which have been shown
to vary with repeated passages [22,35,41,42]. However the band
distribution of SSRBe15739 shifted slightly in the Becker p10 stock
(Figure 7). The upper length estimate for SSRBe15739 (Table S3 in
Text S1) falls into the band distribution observed in Figure 7B, and
the predicted ratios across strains (Table 5) likewise mirror the
observed differences. Thus the CAPRE script met our goal of
conservative length estimation, and allowed correct prediction of
the extreme inter-strain size differential of the homologous SSR
that falls between UL46 and gB (UL27).
PCR validations reveal homopolymers as mutational
hotspots
We also used PCR sequencing to refine and validate selected
areas in the assembly (Tables S2 and S4, and Figure S1 in Text
S1). The majority of these PCR products confirmed divergence in
the newly sequenced strains from the previous mosaic reference
genome, while the remainder corrected SSR-based issues in the
assembly, e.g. for Becker UL3.5 and VP1/2 (UL36), and Bartha
VP1/2 (Tables 1–3 and Table S2 in Text S1). To assess sequence
stability in PRV genomes over time, we PCR-amplified and
sequenced the same regions of parental stocks of these plaque-
purified isolates. We found no base pair differences between 8.8 kb
of the parental and progeny genomes, in ten spatially distributed
PCR comparisons (Table S2 in Text S1).
We and others have previously demonstrated that direct Sanger
sequencing of PCR products, vs. cloning and subsequent sequenc-
ing, provides useful and sensitive detection of minority variants in a
population [78,81]. In a prior sequencing study, we detected
variation at a C6 homopolymer in an HSV-1 stock; plaques picked
from this stock reproduced either homogeneous C6 or C5 variants
[81]. Although we were not searching for minority variants, all of
theabovePCRsequenceswerevisuallyscreened forany evidenceof
such variation. We detected two such sites, one each in PRV Becker
and Bartha, in different homopolymers upstream of ICP22 (US1).
Figure 7. Southern blot of CAPRE-estimated SSR lengths. A)
RFLP analysis of SalI fragments of PRV strains Kaplan (Ka), Becker (Be),
Bartha (Ba), and a Becker stock passaged 10 times in vitro (Be p10).
Positions of one standard marker are noted on the left; another marker
lane is shown between the Bartha and Becker p10 lanes (5 bands: 23 kb,
9.4 kb, 6.6 kb, 2.3 kb, 2 kb). Asterisk (*) at 7 kb in the PRV Bartha lane
highlights a size shift in the fragment containing the Bartha US-region
deletion. B) Southern blot of the same fragments, using a biotinylated
probe matching SSRKa17595 (a perfect 15-mer) to reveal the size of the
SalI fragment containing this site. Without any SSR content, this
fragment would be ,0.55 kb in PRV Kaplan and Bartha, and ,0.74 kb
in PRV Becker. Based on observed fragment sizes, the 1 kb Kaplan and
Bartha fragments each have ,30 copies of this SSR, while the 2.5 kb
average Becker fragment (range 1.6–3.5 kb) has on average ,120
copies (range 58–184 copies). The variable fragment size in PRV Becker
shifts upon passage in vitro (Be p10).
doi:10.1371/journal.ppat.1002282.g007
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region (Figure 1A,C). At a C10 site upstream of ICP22, the majority
of the PRV Becker PCR products reflected a homopolymer length
of ten, while a minority of the products had a length of nine (Figure
S2C in Text S1); these may represent the contributions of viral
nucleocapsid DNA population used as a template. Likewise, at a
different C10 homopolymer upstream of ICP22, PCR sequencing of
PRV Bartha revealed homopolymer variants of nine, ten, and
eleven (data not shown). Although these variants could reflect
polymerase slippage during PCR or Sanger-sequencing of the PCR
products, both PCR products contain nearby C8 homopolymers
that show no minority products. The homopolymer variants
described here, along with accumulating evidence from other
alphaherpesviruses, suggests that homopolymers are mutational
hotspots in PRV as well [78,81,116–119].
Sequence polymorphisms in plaque-purified and
passaged strains
There is limited evidence for sequence polymorphisms in large
DNA virus genomes; these include several studies that noted SSR-
based variation in clonal stocks of herpesviruses [35,78,120],
several recent studies of variation in HCMV DNA from both
clinical and lab-passaged strains [121–124], and the recent
observation of a small number of polymorphic bases scattered
throughout the large DNA genome of Mimivirus [125]. We
therefore used single-nucleotide polymorphism (SNP) detection
software to check for any variation in base calls when HTS data
from each strain were aligned back to the finished genome (see
Methods for details). A small number of bases (0.004–0.03% of
each genome) were indeed called as polymorphic in each plaque-
purified isolate (22 in PRV Kaplan, 37 in Becker, 6 in Bartha).
Unlike HTS genomes with low coverage depth, HTS data for
these viral genome sequences provides deep coverage and a strong
likelihood that these base variations are not sequence errors. An
examination of the percent of reads contributing to each
polymorphic base calls revealed that in most cases, the alternative
base was present in a minority of the sequence reads, from 1–20%
(Figure 8A).
PRV Becker was the only strain with several polymorphic bases
approaching 50–50 variation in the primary versus the alternative
base (Figure 8A). We therefore investigated the stability of these
polymorphic bases in the serially passaged Becker p10 strain.
Figure 8. Percent of data supporting polymorphic base calls in PRV genomes. A) A limited number of polymorphic bases were detected in
the plaque-purified strains Kaplan, Becker, and Bartha; these were analyzed to deduce the percent of sequence data supporting the primary vs.
alternative base calls. The majority of polymorphic sites show 1–20% support for the alternative base call, or 99–80% support for the primary base
call. B) After passaging the purified Becker stock multiple times in vitro (Becker p10), there was no increase in the overall number of polymorphic
bases, and only a slight shift in the degree of support for alternative base calls. C) However in an unpurified historical stock of PRV Kaplan, which is
the parent of the plaque-purified stock used for sequencing, hundreds of polymorphic bases were observed. Despite the larger quantity of
polymorphic bases, the degree of support for the alternative base is similar to that found in the plaque-purified strains. D) Graph displays the
alternative base calls for the four most variant polymorphisms in PRV Becker (41–50% bin), and how these specific bases were called in the Becker
p10 progeny stock (the height of each base letter corresponds to its frequency). These sites display shifts in base frequency in the Becker p10 stock.
doi:10.1371/journal.ppat.1002282.g008
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aligned to the PRV Becker genome for SNP analysis (see Table S1
in Text S1 for details of HTS data generated). We found no
increase in the overall number of polymorphic base calls after
serial passage (Becker: 37, Becker p10: 30), and only a slight shift
in the frequency of observation of the secondary base call
(Figure 8B). Many polymorphic sites in the Becker p10 stock (28
of 30) were in the same position as in the parental, purified Becker
stock but had shifted in allele frequency. An additional 9
polymorphic sites either were lost or gained during the passaging
that produced the Becker p10 stock. The four most polymorphic
sites in the original PRV Becker stock were still called as
polymorphic in Becker p10, but had shifted in allele frequency
(Figure 8D). Interestingly, only one SNP in any of these strains
affected a coding sequence, and this one (P2172A) occurred in the
proline-alanine rich region of Kaplan VP1/2 (UL36) that is
dispensable for viral replication in vitro [95,96]. The SNPs in these
plaque-purified and limited-passage strains were almost exclusively
located in non-coding regions.
Since serial passaging of a plaque-purified population had little
effect on these polymorphisms, we examined variation in one of
the non-purified viral stocks that gave rise to these plaque-purified
isolates. Here we sequenced the oldest viral stock available in the
lab, which is the parent of the plaque-purified PRV Kaplan used
for these studies [62,126]. RFLP profiles of this PRV Kaplan
stock, termed Kaplan n.p. (not purified), matched that of the
plaque-purified PRV Kaplan isolate (Figure 2B). HTS data for
Kaplan n.p. was aligned to the PRV Kaplan genome and used for
SNP calling (see Table S1 in Text S1 for details of HTS data
generated). This stock possessed 547 polymorphic sites relative to
the plaque-purified genome (0.39% of the genome; Figure 8C and
Figure S5 in Text S1). As found for SNPs in the plaque-purified
strains, most alternative base calls resulted from variants present at
1–20% (Figure 7C). Strikingly, the majority of these SNPs occur in
coding regions, and are well-distributed across the PRV genome
(Figure S5 in Text S1). Because these data cannot distinguish how
many polymorphisms are present in any one viral genome of the
Kaplan n.p. stock, versus distributed across the entire viral
population in that stock, we cannot determine the extent of
selection that occurred during plaque-purification. Future se-
quencing technologies that can examine single genomes will be
required to address this. Together with the results above, we
suggest that subtle variations such as these SNPs and homopol-
ymer length variants provide the genetic diversity to help these
strains adapt to future evolutionary pressures.
Defining a new reference genome for PRV
The genome currently used as a reference for PRV is a mosaic
of six strains [30] We therefore propose that the PRV Kaplan
genome presented here (GenBank Accession JF797218) serve as a
new reference genome for PRV. Strain Kaplan contributed 86%
of the sequence in the mosaic reference genome, while the
remainder included sequences from strains Becker, Rice, Indiana-
Funkhauser, NIA-3, and TNL. Accordingly, we compared our
complete PRV Kaplan genome to that of the original mosaic
reference genome. Not surprisingly, the majority of protein coding
differences between Kaplan and the mosaic genome (81%; 141 of
173 amino acid (AA) differences) occur in twelve of the thirteen
proteins that were originally sequenced from non-Kaplan strains:
gB (UL27), ICP18.5 (UL28), ICP8 (UL29), UL43, gC (UL44), TK
(UL23), ICP0 (EP0), gG (US4), gI (US7), gE (US8), US9, US2 (see
Table S5 in Text S1 for specific AA differences).
Several of these sequence differences significantly affect the
resulting protein because of frameshifts in the strains used for the
mosaic genome. The largest frame-shift changes 46 AAs in the
extracellular domain of gG (US4), which has been mapped as a
chemokine-binding region [67]. The gG sequence in the mosaic
genome was derived from PRV strain Rice. Alignment of the three
new PRV strain genomes, along with two geographically distinct
gG sequences deposited in GenBank (Ea, China: AY319929, NIA-
3, Ireland: EU518619), revealed that the PRV Rice strain included
in the original mosaic genome is the only one to possess this frame-
shift sequence and cannot be representative of most PRV strains.
Similarly, all three new genomes share a common sequence of
ICP8 (UL29; only 1 AA difference in PRV Becker; Table 3), which
is a single-stranded DNA binding protein that functions in both
replication and recombination of the viral genome [127,128]. This
new ICP8 sequence differs from the TNL strain sequence of ICP8
found in the mosaic PRV reference at a total of 20 residues (Table
S5 in Text S1), including a compensated frame-shift that affects a
stretch of 8 amino acids immediately flanking the zinc finger
domain [129].
Conclusions
Herpesvirus genomes: a microcosm of HTS eukaryotic
genome assembly. Herpesviruses are among the largest DNA
virus genomes and cause significant human disease, making the
characterization of their sequence diversity a priority. While viral
discovery screens using HTS often produce sufficient data to
assemble entire RNA virus genomes [130–136], the ten-fold larger
size of herpesvirus genomes means that only directed sequencing
projects have thus far produced data on new strains [81,120,
137,138]. Herpesvirus genomes represent a microcosm of the
features found in eukaryotic and bacterial genomes: abundant
SSRs, histone modifications, splice sites, and microRNAs, among
others, with frequent recombination at the large inverted repeats.
An improved understanding of how these elements vary in these
viral genomes may shed light on related sequence features in larger
genomes, where sequencing of repeated generations or multiple
related isolates may be prohibitive in cost or computational time.
For instance, while the G/C coverage bias seen in these
herpesvirus genomes has been previously observed in higher
organisms [59,60], there has not yet been sufficient depth of
coverage and variety of G/C-rich sequence structures to correlate
specific sequences with specific coverage-depth consequences. The
G/C-bias of PRV and HSV-1 genomes along with their deep
sequence coverage (.2,000-fold on average) provide data for
future exploration of these issues, which will then provide insight
relevant to all future sequencing endeavors.
Multiple glycoprotein mutations in the PRV Bartha vac-
fcine strain. Herpesvirus virions are coated in glycoproteins,
which play a major role in viral spread from cell to cell and host to
host, and are thus crucial to pathogenesis and vaccination
strategies in vivo [8,9,139–141]. PRV has 11 glycoproteins, with
functions including fusion (gH, gL, and gB), cellular attachment
(gC, gD), rate of virion penetration (gN, gM), triggers of host
immunity (gG, gI), viral transport in axons (gE), and virion egress
(gK). The genome of PRV Bartha reveals mutations in genes that
encode the majority of this suite of glycoproteins. Previously
known changes in PRV Bartha that affect glycoproteins included
the US-region deletion that removes gE and gI, a signal sequence
mutation of gC, and a residue change affecting the N-glycosylation
site of gM; all of these have also been shown to affect PRV
Bartha’s spread in culture, and the role of gE and gI have been
confirmed to affect the attenuation of PRV Bartha’s virulence in
vivo [21,28,31,61–65,142]. To this list, we now add several
mutations in the coding sequences of gN, gB, gH, gG, and gD,
which are unique to PRV Bartha and are not seen in the virulent
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relevance of these sequence differences to the attenuation of PRV
Bartha’s virulence in vivo, and their potential use in aiding the
development of an HSV-1 vaccine strain.
SSRs and homopolymers fuel inter- and intra-strain
diversity. Prior to this study, few PRV SSRs had ever been
analyzed for potential inter-strain variation [86,115,143–145]. For
decades, researchers have known that certain regions of the PRV
and HSV-1 genomes are variable by RFLP analysis of repeatedly
passaged virus stocks [22,35,42,43], but little work has been done
to elucidate the basis of this variation. The most variable sections
of the PRV genome by RFLP analysis are located within BamHI
fragments 10 and 12 (Figure 2), which represent the IR and TR
copies of ICP22 (US1) and its upstream region. ICP22 has the
highest inter-strain variability of any PRV protein (Figure 5). This
region includes both areas of homopolymer length variation found
in the plaque-purified strains (see above), has a large complement
of SSRs of all size classes (Figure 1C), contains several SNPs in its
flanking untranslated regions in every strain (Figure S5 in Text
S1), and was highly refractory to PCR analysis (data not shown).
Taken together, this region shows uniquely high variability that
extends well beyond the prior RFLP observations. The ICP22
(US1) protein of PRV has been virtually unstudied at the protein
level, so that further work is required to understand its role and the
significance of its variability between strains [86,87]. Our analysis
thus reveals a likely target for the historical variability of
restriction-digest fragments of this region of the PRV genome,
and suggests that similar features could be associated with the
classically-variable fragments of the HSV-1 genome as well.
Although larger SSRs are more noticeable to the eye,
homopolymers of six or more consecutive bases are the most
abundant class of SSRs in PRV and all viral genomes thus far
examined. These numbers would only increase if we included
homopolymers of five or fewer. Homopolymers have been
previously suggested as mutational hotspots for HSV, but only in
the context of two genes where they have been well-studied. First,
resistance to the drug acyclovir and related nucleoside analogs is
often mediated by changes in homopolymers of the TK (UL23)
gene, an observation documented in several alphaherpesvirus
species [117–119,146–148]. Second, variation in the human
antibody response to HSV occurs because of homopolymer
mutations in the gG (US4) gene [149,150].
We now suggest that homopolymers across the genome are
mutational hotspots for evolutionary diversity in all alphaherpes-
virus strains, and potentially in other virus families as well.
Examples from the literature support this, with a wide array of
examples mentioned in passing as part of other studies: the
C4RC6 (wild-typeRmutant) shift in HSV-1 strain 17 that caused
early struggles in recognizing ICP34.5 (RL1) as a valid gene [151],
aC 7RC6 deletion in the vhs (UL41) gene of the HSV-2 HG52
strain [152], a T7RT6 mutation in UL5 of an attenuated Marek’s
disease virus genome [153], a spontaneous G7RG8 insertion in gE
(US8) in an engineered strain of PRV [154], among others
[78,81,99,100,155–158]. These examples, in conjunction with the
clinical examples in TK and gG above, and our own data
presented here, demonstrate the homopolymer mutations can
occur throughout the herpesvirus genome. The aforementioned
studies of TK and gG sequences in clinical samples demonstrate
that homopolymer mutations occur readily during human
infection. Together these data suggest that this highly abundant
class of SSRs could provide a major source of adaptive variation
for viral strain divergence. Beyond these viruses, homopolymer
variation has been previously found in organisms from yeast to
worms to humans [45,159–162]. A significant proportion of
cancer-associated mitochondrial DNA mutations occur at homo-
polymers [163–165]. As described earlier, changes in SSR length
have been demonstrated to affect gene expression, protein
interactions, and chromatin binding, among other functions
[45,47–50]. Future study of homopolymeric and SSR-based
variation in herpesviruses may help to reveal the evolutionary
fitness contributions of these mutational hotspots.
Methods
Virus stocks and passaging
PRV Bartha is a highly passaged vaccine strain, derived from
the original Aujeszky strain which was isolated in Hungary [29].
PRV Becker is a virulent field isolate from dog, originally isolated
at Iowa State University (USA), with subsequent laboratory
passage [166]. PRV Kaplan is a virulent strain with extensive
laboratory passage, likely derived from the Aujeszky strain
[126,167]. All viral stocks were grown and titered on monolayers
of PK-15 pig kidney cells (ATCC cell line CCL-33). Stocks of each
virus were triple-plaque-purified, expanded, and used to infect
cells for a nucleocapsid DNA preparation. Viral nucleocapsid
DNA was prepared by previously published methods
[81,168,169].
A passaged PRV Becker strain (Becker p10) was produced by
infecting a monolayer of cells with the plaque-purified stock at a
multiplicity of infection (MOI) of 0.01. At full cytopathic effect
(CPE), a small aliquot of this virus was used to directly infect a
fresh monolayer of cells, and this procedure was repeated a total of
ten times. The resulting stock was used to prepare nucleocapsid
DNA for sequencing and RFLP analysis.
Illumina library preparation and sequencing
DNA sequencing was carried out according to manufacturer
protocols and reagents, using an Illumina Genome Analyzer II
with SCS 2.3 software at the Princeton University’s Lewis-Sigler
Institute Microarray Facility. Five micrograms of nucleocapsid
DNA was sequenced for each strain, using either one (PRV
Kaplan, Becker p10) or two (Becker, Bartha, Kaplan n.p.) flowcell
lanes. All sequencing runs were 75 cycles in length, except for one
Becker and one Bartha lane of 51 cycles. The total number of
sequence reads generated for each strain are listed in Table S1 (in
Text S1). All Illumina sequence data has been deposited at the
NCBI Short Read Archive under Accession ID SRA035246.1.
Initial data processing and quality control
Initial data processing included several steps: 1) Illumina output
converted to a standard file format, 2) library adaptor contami-
nants removed, 3) host genome sequences removed, 4) mononu-
cleotide reads removed, 5) duplicate runs combined, and 6) quality
and length trimming applied. All data and scripts described here
are available at a genome-browser (http://viro-genome.princeton.
edu) and data analysis website (http://genomics-pubs.princeton.
edu/prv) hosted by Princeton University’s Lewis Sigler Institute.
First, a script from the FASTX-toolkit developed by the
Hannon lab (http://hannonlab.cshl.edu/fastx_toolkit/) was used
to remove adaptor sequences resulting from the Illumina library
preparation. Next, because these PRV viruses were grown in pig
kidney cells, we used the Bowtie software package [170] to
compare the sequence data against the Sus scrofa pig genome
(NCBI build 1.1) and remove any sequences perfectly matching
the host genome. The percent of contaminating host DNA is listed
for each strain in Table S1 (in Text S1). Finally, we filtered out any
reads that were entirely mononucleotides, which we previously
found can confound genome assembly [81]. Finally, where
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runs.
Two scripts were then used to remove poor-quality base calls
from the end of the Illumina short-sequence reads. First, we used
an adapted version of the quality-trimming script (TQSfastq.py)
from the SSAKE de novo assembly software package [171]. We
modified the parameters for quality threshold (T) and consecutive
bases (C) above threshold, producing trimmed datasets for each
strain with the default settings of T10, C20 or a more stringent
quality control trimming of T20, C25. We then used the more
stringently-filtered dataset as the input to a universal length
trimmer from the FASTX toolkit, which truncated all sequences in
the data file at a specified length, in this case either 41 or 51 bp.
This generated four quality-filtered and trimmed datasets for each
strain.
De novo assembly
The SSAKE de novo assembler [171] was used to join the short
single-end Illumina reads into longer blocks of continuous
sequence, or contigs. Each of the four FASTQ files generated
above was assembled by SSAKE under two independent
conditions. First the default settings of SSAKE were used. Then
the trim option was applied to each of the four input files during
assembly, to trim two bases from the end of each contig once all
possible other joins had been exhausted. This produced a total of
eight SSAKE assemblies for each viral strain. These eight
alternative sets of SSAKE contigs were combined and used as
inputs to a long-read assembler, based on an approach used
successfully for HTS assembly of HCMV genomes [137].
The Staden DNA sequence analysis package was used for
further genome assembly of the long sequence contigs generated
by SSAKE [172,173]. The Pregap function was used to process
and rename all contigs, which were then assembled using the
standard ‘‘independent assembly’’ function of Gap4, with default
settings. Contigs were sorted into descending size order and
outputted as a normal consensus. This generated a multi-line
FASTA formatted file that we inputted to NCBI’s blast2seq
program [174], for comparison to the PRV mosaic reference
genome (Accession number NC_006151) [30]. This program
produced pairwise alignments of each contig against the reference
genome, allowing us to order the contigs along the genome and to
flag potential bad joins generated by the assemblers. Contigs with
suspicious joins were visually inspected in the Gap4 Contig Editor.
These joins often occurred at extended runs of Gs or Cs, where
disparate regions of the genome were joined solely as a result of
overlapping mono-nucleotide stretches. The final assembly was
created in gap4 by manually joining the minimum possible
number of contigs. Final genome assemblies were further
improved by PCR validation and repeat expansion, and verified
by RFLP analysis (see below). All genome sequences are deposited
with annotations (described below) in the NCBI Nucleotide
(GenBank) collection: PRV Bartha: JF797217, PRV Kaplan:
JF797218, PRV Becker: JF797219.
Annotation of genes and coding sequences
Annotation of the new PRV genome sequences was created by
BLAST homology-based transfer of annotations from the prior
mosaic reference genome (NC_006151) to PRV Kaplan, using
previously described scripts [81,174]. Annotations of PRV Kaplan
were then similarly transferred to PRV Becker and Bartha. Scripts
for automated annotation transfer are available for download at
http://genomics-pubs.princeton.edu/prv. Annotation transfer can
fail when several base pairs of divergence or indels occur at the
gene boundaries; these instances were addressed by manually
varying the BLAST parameters to improve alignment and/or
visually inspecting a pairwise alignment of the new strain against
the reference. Entrez Gene IDs for all PRV, HSV-1 and VZV
genes are listed in text format in Text S1, as well as hyperlinked in
Table S6.
Sequence alignment
The completed PRV genomes were aligned using the mVista
genomics analysis tool with global LAGAN alignment [175,176].
The VISTA Browser was used to visualize genome-wide conserva-
tion based on this alignment. The VZV genome (NC_001348) was
used as an outgroup for tree generation in MacVector v11.1.2
(MacVector, Inc.) by the neighbor-joining method. One thousand
rounds of bootstrap analysis provided confidence values for the
branch points. Similar trees were obtained using alternative
methods, such as clustering by the unweighted pair-group method
with arithmetic mean (UPGMA) or following the precedent of
single-gene comparison of the variable gC (UL44) nucleotide
sequence [33,34,177].
RFLP and Southern Blot analysis
Digestion of nucleocapsid DNA was performed to verify
predicted fragment sizes corresponding to the newly assembled
genomes. RFLP reactions utilized 4 mg nucleocapsid DNA per
reaction, while Southern Blot digests used 1 mg nucleocapsid
DNA. Reactions included viral nucleocapsid DNA, BamHI or SalI
High Fidelity restriction enzymes (New England BioLabs), and
supplied buffers and reagents as directed by the manufacturer;
these were incubated at 37uC overnight. The addition of 5 mg/ml
of ethidium bromide to an 0.8% agarose gel and to the 1X TAE
running buffer allowed for enhanced UV visualization of
fragments. Gel electrophoresis of the digested samples ran at 30
volts for approximately 48 hours at 4uC.
Southern blotting used the NEB Phototope-Star detection kit
for nucleic acids (New England BioLabs) according to manufac-
turer’s instructions. Briefly, the SalI RFLP gel was transferred to a
nylon membrane and UV crosslinked. After blocking, the boiled
probe was hybridized to the membrane overnight at 68uC, and
detected by sequential application of streptavidin, biotinylated
alkaline phosphatase, and finally the chemiluminescent reagent
CDP-Star (New England BioLabs). The biotinylated probe was
synthesized and HPLC-purified (Integrated DNA Technologies/
IDT) to match SSRKa15795 and the homologous SSRs in other
strains. The probe consisted of three tandem copies of the SSR
unit (a 15 mer), using the reverse-strand sequence of the SSR to
allow for the incorporation of a biotinylated thymidine (T*, one
per oligonucleotide): 59-TCTCCCCTCCGTCCCTCTCCCC-
T*CCGTCCCTCTCCCCTCCGTCCC-39.
PCR validation of selected regions
Primers were designed for the amplification of several genes
from nucleocapsid genomic DNA of all three PRV strains and
their parental lysate DNA. Primer pairs are listed in Table S4 (in
Text S1). To allow for easier PCR access, template DNA was
boiled for 5 minutes and immediately cooled on ice. Initial PCRs
were executed in 50 ml volumes using 1 ml of template. The
reaction setup contained 1X Advantage 2 DNA polymerase
(Clontech), 1X buffer as supplied by the manufacturer, 2%
dimethyl sulfoxide, 1.2 M betaine (Sigma), each primer at a
concentration of 0.5 mM, and each deoxynucleoside triphosphate
at a concentration of 250 mM. Initial PCR conditions using an
Eppendorf thermocycler are as follows: Initial denaturation at
95uC for 3 minutes, followed by 25 cycles of denaturation at 95uC
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primer extension at 68uC for 2 minutes, with a final extension step
at 68uC for 10 minutes. For more difficult gene amplifications an
alternate reaction setup was used: 0.6 U Takara Ex Taq
polymerase (Takara); 1X buffer as supplied by the manufacturer;
5% dimethyl sulfoxide; each primer at a concentration of 1 mM;
each deoxynucleoside triphosphate, with equal amounts of dGTP
and 7-deaza-29-dGTP (Sigma Aldrich), at a concentration of
200 mM; and 1 ml of template DNA for a total reaction volume of
25 ml. Alternate PCR conditions were also used: Initial denatur-
ation at 95uC for 5 minutes, followed by 40 cycles of denaturation
at 95uC for 1 minute, gradient primer annealing temperatures
from 55–75uC for 1 minute, and primer extension at 72uC for 2
minutes, with a final extension step at 72uC for 7 minutes.
For PCR validations of PRV Becker and Bartha parental DNA,
we used lysates from the oldest available laboratory stocks of each
virus. HTS data had already revealed that the oldest available
stock of PRV Kaplan in the lab contained several hundred
polymorphic base calls (described in Results and Figure 7C), so we
instead compared results from PCR amplification of a stock of gH-
null PRV Kaplan provided by Mettenleiter and colleagues [178].
By selecting these stocks, all of which were historically separated
from the sequenced strains by multiple passages, we aimed to
maximize the opportunity to detect sequence divergence relative
to the new genomes.
Western blot analysis
Cell lysates from PK15 cells were collected at 12 and 24 hours
post infection into ice cold PBS and centrifuged for 3 minutes to
pellet the cells and allow aspiration of the supernatant. The cells
were lysed with RIPA light buffer (50 mM Tris/HCl (pH 8.0),
150 mM NaCl, 5 mM EDTA, 1% NP-40, 0.1% SDS, 0.1% Triton
X-100). Insoluble cell debris was pelleted by centrifugation at 4uC,
and the supernatant was collected for protein measurement. 50 mg
of protein from the RIPA supernatant was brought up to a common
volume using Laemli buffer (100 mM Tris/HCl (pH 6.8), 4% SDS,
200 mM DTT, 0.2% bromophenol blue, 20% glycerol) for each
sample. These were boiled for 5 minutes at 95uC, electrophoresed
through a 10% SDS-PAGE gel, and transferred to a nitrocellulose
membrane (Whatman PROTRAN) using a Bio-Rad semi-dry
transfer cell. The membranes were blocked using 5% non-fat milk
and PBS-T. Primary and secondary antibodies were diluted in 1%
non-fat milk in PBS-T. Proteins were visualized using rabbit
polyclonal antibodies for gH (UL22) (1:2000) and VP1/2 (UL36)
(1:10,000); mouse monoclonal antibodies for gB (UL27) (1:1000),
VP5 (UL19) (1:1000) and b-actin (1:1000); goat horseradish
peroxidase-conjugated secondary antibodies; and SuperSignal
chemiluminescence reagents (Thermo Scientific) as indicated by
the manufacturer’s instructions. Band intensities were measured
using the ImageJ (NIH) Gel Analyzer module.
Coverage depth and polymorphic base detection
For quality control assessment of the finished genome
assemblies, we used the Bowtie [170] and Samtools [179] software
packages to assess the depth of sequence coverage and check for
variant base calls. First, Bowtie (option –best) was used to align the
Illumina sequence reads used for assembly against the finished
genomes. Then three Samtools commands (view, sort, and pileup,
with default options) were used to format the Bowtie alignment
output and measure the depth of sequence read coverage (a pileup
file) at each base of the finished genome sequence. The Integrated
Genome Browser (IGB, [180]) was used to visualize each pileup
graphically (a wiggle or wig plot; Figure S1 in Text S1). Finally, the
Samtools varFilter command (default options, depth 40,000) was
used to detect any variant base calls in the alignment of sequence
reads back to the finished genomes. Assessment of polymorphic
bases in the passaged (Becker p10) and non-purified (Kaplan n.p.)
genomes was done by aligning sequence data for these stocks
against the finished genome from the matching plaque-purified
stock (i.e. Beckerp10 was aligned to the finished PRV Becker
genome, and Kaplan n.p. to the PRV Kaplan genome).
Additional filtering was used to remove potential erroneous
SNP calls [181]. These filters were based on a manual
examination of all SNPs in strains Kaplan and Bartha. First,
SNP locations were screened and flagged if they met any of the
following criteria: adjacent to homopolymers of length $6,
directional strand bias .85%, or overall coverage depth ,100.
All flagged SNPs were manually examined using the Integrative
Genomics Viewer (IGV) to display sequence reads aligned to the
genome sequence [182]. SNPs with likely homopolymer-based
alignment error, unidirectional sequence read support, or signs of
site-specific error were discarded [181]. Both filtered and
unfiltered lists of DNA polymorphisms are available for download
at http://genomics-pubs.princeton.edu/prv. Frequency distribu-
tions of polymorphic base calls were plotted using Prism v5.0
(GraphPad Software, Inc.).
Estimation of G/C coverage bias
To measure G/C coverage bias, we followed the method of
Frazer and colleagues [59] (Figure S2A in Text S1). Briefly, each
genome was divided into sequential 10-mers. The coverage depth
of each 10-mer was determined by taking the average coverage
depth of the bases in the 10-mer. These were placed into bins
according to G/C content, i.e. the number of G or C bases in the
10-mer. We recorded the number of 10-mers and the median
coverage depth in each bin.
Coverage Adjusted Perfect Repeat Expansion (CAPRE)
We used the coincidence of very high sequence coverage at
perfect repeats in each PRV genome to estimate the actual length
of these SSRs. The CAPRE script was applied only to selected
regions meeting these criteria: an intergenic region, with coverage
more than two standard deviations from the median, and centered
on a perfect SSR with repeating units exceeding the median length
of the filtered Illumina sequence reads. For each intergenic region
meeting these criteria, an SSR unit that most closely matched the
median Illumina read length was defined, and its genome position
boundaries noted. The CAPRE script first determined the G/C
content of the inputted SSR unit and used the G/C coverage bins
above to obtain the expected median coverage depth for this SSR
unit. The script then took the defined SSR unit boundaries and
measured their observed sequence coverage. The script then
estimated how many copies of the defined SSR unit would be
needed to achieve the expected coverage depth, and inserted the
appropriate number of SSR units into the genome sequence. The
position of subsequent CAPRE regions was iteratively adjusted to
account for expansion of the preceding region. To produce upper
and lower estimates of SSR length, we ran the CAPRE script
again and estimated the SSR length according to the upper and
lower quartiles of observed sequence coverage (Figure S2 in Text
S1) for each G/C content, instead of the median.
Short Sequence Repeats (SSRs) comparison between
strains
The location of SSRs throughout the PRV genome was mapped
using MsatFinder and Tandem Repeat Finder (TRF) [183,184].
MsatFinder detects perfect tandem repeats from homopolymers (1
Inter-Strain Diversity of Alphaherpesviruses
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homopolymers of at least 6 bases long, and the following minimum
number of repeating units for larger microsatellites: 5 units for di-,
4 units for tri-, and 3 units for quadri- to hexa-mers. TRF finds
larger repeating units, and was designed to detect imperfect
repeats that include minor base variations and indels. We ran TRF
v4.04 with the following parameters: match 2, mismatch 5, delta 5,
PM 80, PI 10, minScore 40, and maxPeriod 500. TRF output was
pruned to remove overlapping repeats, preserving the SSR with
higher alignment score. We utilized only TRF output with an
alignment score of at least 40. This value is commonly used for
other genome analyses, and we validated this cutoff for PRV by
analyzing the number of repeats that would occur by chance in a
shuffled version of the PRV Kaplan genome. Analysis of this
shuffled genome detected 73 TRF SSRs in the randomized
genome, vs. 637 in the PRV Kaplan genome. Thus approximately
1 out of every 10 TRF repeats might occur by chance, due to
nucleotide composition.
Mapping and comparison of homologous SSRs on related PRV
genomes were done by previously described methods [49,125].
Briefly, we first aligned the complete PRV genomes using the
mVista genomics analysis tool (LAGAN alignment option)
[175,176]. Sections of this alignment containing SSRs, as mapped
in the PRV Kaplan genome, were screened for comparable SSRs
in the orthologous regions of the Becker and Bartha genomes. This
process was repeated using the lists of SSRs found in the PRV
Becker and Bartha genomes. Screening of SSRs using all three
genomes as a starting point allowed detection of SSRs that do not
occur in all three strains, whose length or purity of repeating units
is below threshold in PRV Kaplan but detectable in Becker or
Bartha, or whose sequence is divergent enough to be scored as a
separate SSR. Table S7 contains a full list of SSRs found in these
three genomes. The identifier for each SSR denotes the genome
from which its mapping was derived, as well as its starting position
in that genome (e.g. SSRKa151).
Supporting Information
Text S1 This PDF file provides supporting tables, figures,
legends, and text. Tables S1–S5 include additional data
described in the text. Legends describe data in the accompanying
Figures S1–S5. Supplementary text lists accession numbers (Entrez
Gene IDs) for all genes.
(PDF)
Table S6 This Excel file displays the percent of inter-strain
protein variation in PRV, HSV-1, and VZV, along with
hyperlinked Entrez Gene IDs and protein names.
(XLS)
Table S7 This Excel file provides a comprehensive list of SSRs
detected in PRV Kaplan, Becker, and Bartha, with accompanying
data on their location and characteristics.
(XLS)
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